GeneDx Holdings Corp. income statement WGS

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, GeneDx Holdings Corp. reported revenue of $427.5 million, up 40.0% from the year before. It recorded a net loss of $21.0 million. The operating loss came to $13.1 million, an operating margin of -3.1%. Diluted earnings per share were -$0.73. Over the twelve months ended Jun 30, 2026, revenue was $454.4 million and the net loss was $106.4 million. Across the 5 fiscal years shown, revenue grew from $212.2 million in fiscal 2021 to $427.5 million in fiscal 2025, about 19.1% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
454
+25.4%
428
+40.0%
305
+50.8%
203
-13.7%
235
+10.6%
212
Cost of revenue
139
+17.0%
129
+16.5%
111
-1.3%
113
-56.9%
261
+14.3%
229
Gross profit
315
+29.5%
298
+53.4%
194
+116.0%
90
+436.5%
-27
-61.1%
-17
Research and development
84
+64.7%
72
+57.5%
46
-21.5%
58
-32.4%
86
-18.0%
105
Selling, general and administrative
—
239
+39.2%
172
-14.0%
200
-40.9%
338
+6.1%
319
Other operating income (expense)
—
0
0
+100.0%
-2
—
—
Operating expenses
—
311
218
—
—
—
Operating income
-92
-1800.3%
-13
+43.7%
-23
+87.1%
-181
+73.0%
-668
-49.6%
-446
Other income (expense)
-14
-256.1%
-8
+72.6%
-29
-853.7%
4
-94.4%
70
-65.3%
201
Pretax income
-106
-7020.2%
-21
+59.8%
-53
+70.2%
-177
+70.5%
-598
-143.7%
-245
Income tax
0
-52.3%
-0
+66.2%
-0
+63.0%
-1
+98.1%
-49
0
Net income
-106
-7664.5%
-21
+59.8%
-52
+70.3%
-176
+68.0%
-549
-123.7%
-245
Basic EPS
-3.64
-7322.6%
-0.73
+62.4%
-1.94
+73.2%
-7.23
+86.5%
-53.63
-2262.6%
-2.27
Diluted EPS
-3.72
-7649.4%
-0.73
+62.4%
-1.94
+73.2%
-7.23
+86.5%
-53.63
-2262.6%
-2.27
Weighted average shares, basic
29
+4.7%
29
+6.5%
27
+10.6%
24
+137.5%
10
-90.5%
108
Weighted average shares, diluted
29
+0.2%
29
+6.5%
27
+10.6%
24
+137.5%
10
-90.5%
108
Other measures
Depreciation and amortization
11
+21.8%
10
+21.5%
8
-59.9%
20
-60.6%
50
+129.3%
22
EBITDA
-82
-666.8%
-3
+77.3%
-15
+90.5%
-161
+74.0%
-618
-45.6%
-424
Interest coverage
—
—
—
—
-208.19x
-157.37x
Margins
Gross margin
69.37%
69.74%
63.64%
44.43%
-11.40%
-7.82%
Operating margin
-20.34%
-3.06%
-7.60%
-89.15%
-284.48%
-210.25%
Pretax margin
-23.39%
-4.94%
-17.23%
-87.23%
-254.81%
-115.64%
Profit margin
-23.40%
-4.92%
-17.12%
-86.77%
-233.91%
-115.64%
EBITDA margin
-17.94%
-0.81%
-5.01%
-79.43%
-263.17%
-199.98%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Services-Health Services (SIC 8000)
Listed as
WGS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Stamford, CT
SEC filer status
Large accelerated filer
SEC CIK
1818331
Former names
Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)

Other Services-Health Services companies

All 17 Services-Health Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.